{'fraction_non_alphanumeric': 0.023284313725490197, 'fraction_numerical': 0.004901960784313725, 'mean_word_length': 5.8655462184873945, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Autoimmune‐like chronic hepatitis induced by olmesartan

Drug liver-induced injury (DILI) attributed to minocyclin, alpha methyldopa, or nitrofurantoin may be responsible for chronic liver damage that mimics the biological and/or histological features of chronic autoimmune hepatitis and, in rare cases, progresses to cirrhosis. Olmesartan medoxomil is an antihypertensive drug that acts by blocking the angiotensin II receptor and is metabolized into its pharmacologically active form, olmesartan, in the intestine and in the liver before being released into the systemic circulation. Since 2012, several teams have reported olmesartan-associated sprue-like enteropathy. Except for one case of nonalcoholic steatohepatitis, no liver injury related to olmesartan has been reported in the literature to our knowledge.